Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period

NCT01646177 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01646177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01646177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients With Moderate to Severe Plaque Psoriasis With a Long-Term Extension Period
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
July 28, 2012
Completion date
July 22, 2019
Enrollment
1,346 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis